We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Therapeutic Delivery – Products

Blacktrace Launches Particle Works – the New Dedicated Particle Engineering Brand content piece image
Product News

Blacktrace Launches Particle Works – the New Dedicated Particle Engineering Brand

Blacktrace Holdings Ltd is excited to announce the launch of Particle Works, a spin out of Dolomite Microfluidics.
Isolation of High Purity Exosomes content piece image
Product News

Isolation of High Purity Exosomes

AMSBIO is a leading supplier of high purity exosomes using isolation methods including traditional differential and gradient ultracentrifugation, immunoaffinity, size exclusion chromatography as well as precipitation / low speed centrifugation.
Get a High-Resolution View of Your Lipid Nanoparticles content piece image
App Note / Case Study

Get a High-Resolution View of Your Lipid Nanoparticles

Lipid nanoparticles (LNP) play a key role in effectively protecting and transporting mRNA to target cells in mRNA-based vaccines and therapeutics. To ensure the quality and safety of LNP, lipid components and associated impurities/degradants need to be carefully characterized in raw materials and formulation.
NanoGenizer High Pressure Homogenizer for Nanomaterials content piece image
Product News

NanoGenizer High Pressure Homogenizer for Nanomaterials

NanoGenizer, a lab-scale microfluidic high pressure homogenizer, offers effective performance on particle size reduction and cell disruption.
Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions content piece image
Product News

Beckman Coulter Introduces Antipsychotic Drug Testing To Address Unmet Clinical Need for More Than 69 Million People Living With Serious Mental Conditions

Beckman Coulter announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.
Grace Makes CPhI Debut with Advanced Carrier Solution for Challenging Liquid APIs content piece image
Product News

Grace Makes CPhI Debut with Advanced Carrier Solution for Challenging Liquid APIs

Grace will Exhibit at CPhI Worldwide 2021, Virtually and In-Person at Booth 11F26 at Fiero Milano, Milan, Italy.
Cryopreservation Excipient Helps Accelerate Cell Therapy Product Development   content piece image
Product News

Cryopreservation Excipient Helps Accelerate Cell Therapy Product Development

AMSBIO has launched STEM-CELLBANKER® EX - a next-generation cryopreservation product that eliminates the need for the traditional washing steps required in cell therapy product development.
Defined and Controllable Extracellular Matrix for Cell Culture content piece image
Product News

Defined and Controllable Extracellular Matrix for Cell Culture

Biochemically defined and animal-free - Mussel Adhesive Protein based matrix (MAPtrix™) from AMSBIO provides a highly defined and controllable recombinant extracellular matrix (ECM) for cell culture, which can be tailored to the specific needs of particular cell types.
Highly Efficient Exosome Isolation & Purification Tools content piece image
Product News

Highly Efficient Exosome Isolation & Purification Tools

AMSBIO is a knowledgeable supplier of products dedicated to exosome research that includes high quality reagents and kits that are quick, affordable and easy to use. The latest addition to this portfolio is a new range of tools for isolating and purifying overall or specific exosome sub-populations from small volumes of sample in an efficient, faster and cheaper way.
Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial content piece image
Product News

Avacta Announces First Patient Dosed in AVA6000 Pro-Doxorubicin Phase I Clinical Trial

Avacta Group plc is pleased to announce that the first patient has been dosed in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin.
Advertisement